Group 1 - Luye Pharmaceutical has launched Rotigotine Luye in the UK, a generic version of Neupro®, for treating early and advanced idiopathic Parkinson's disease and moderate to severe idiopathic restless legs syndrome [1] - Rotigotine Luye is the first generic version of Neupro® to be launched in the UK, demonstrating bioequivalence with the original product [1] - The product features a smaller patch size, 8% smaller than Neupro®, and has a lower drug load while maintaining the same release dosage [1] Group 2 - Parkinson's disease affects over 10 million people globally and is the second most common neurodegenerative disease, leading to significant mobility and mental health issues [2] - Restless legs syndrome affects approximately 3% of the global population, causing an irresistible urge to move the legs, which can severely disrupt daily activities [2] - Rotigotine, as a dopamine receptor agonist, improves both motor and non-motor symptoms in Parkinson's patients and alleviates symptoms in restless legs syndrome patients [2] Group 3 - Luye Pharmaceutical has a strong focus on the central nervous system treatment field, with a portfolio of internationally competitive innovative drugs and formulations [3] - The company has several approved products, including Erzofri® and Rykindo® in the US, and Ruoxinlin® and Jinyouping® in China [3] - Multiple first-in-class innovative drugs are in clinical stages, including LY03020, LY03021, and LY03015, targeting various mechanisms [3]